Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Intraperitoneal delivery of nanoparticles for cancer gene therapy

    Access Status
    Fulltext not available
    Authors
    Hallaj-Nezhadi, Somayeh
    Dass, Crispin
    Lotfipour, Farzaneh
    Date
    2013
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Hallaj-Nezhadi, Somayeh and Dass, Crispin R. and Lotfipour, Farzaneh. 2013. Intraperitoneal delivery of nanoparticles for cancer gene therapy. Future Oncology 9 (1): pp. 59-68.
    Source Title
    Future Oncology
    DOI
    10.2217/FON.12.171
    ISSN
    1479-6694
    URI
    http://hdl.handle.net/20.500.11937/45786
    Collection
    • Curtin Research Publications
    Abstract

    Nanoparticle-based gene delivery systems may be more efficient for administration of therapeutic genes to solid tumors and cancer metastases, owing to the numerous advantages in terms of enhanced tissue penetrability, improved cellular uptake and targeted gene delivery to the cells of interest compared with other gene delivery systems. Intraperitoneal (IP) delivery of therapeutic agents offers special merits because of the anatomical situation of peritoneum for local cancer therapy. Via the IP administration route, it is possible to target the therapeutic agents exactly to the target cells and protect healthy tissues outside the peritoneal cavity from side effects. IP delivery could be applicable for the treatment of disorders of organs in the peritoneal cavity covered with peritoneum and subperitoneal connective tissue, including cancers such as ovarian and gastric. The goal of this article is to review the current state of IP delivery of nanoparticles for cancer gene therapy.

    Related items

    Showing items related by title, author, creator and subject.

    • Treatment of lung cancer using nanoparticle drug delivery systems
      Chandolu, V.; Dass, Crispin (2013)
      Context: One of the leading causes of cancer-associated deaths in most men and women in the Western world is lung cancer. There are various types of treatments depending on the type and the stage of the cancer. A recent ...
    • Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy
      Hallaj-Nezhadi, S.; Lotfipour, F.; Dass, Crispin (2010)
      While the systemic route of administration enables therapeutic genes to spread through the bloodstream and access target cells, it is a challenge to achieve this. Several studies demonstrate that systemic administration ...
    • Diaminododecane-based cationic bolaamphiphile as a non-viral gene delivery carrier
      Khan, M.; Ang, C.; Wiradharma, N.; Yong, L.; Liu, S.; Liu, Lihong; Gao, S.; Yang, Y. (2012)
      The advancement in gene therapy relies upon the discovery of safe and efficient delivery agents and methods In this study, we report the design and synthesis of a cationic bolaamphiphile as a non-viral gene delivery agent ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.